|
US2016175356A1
|
|
Formulations of calcium and phosphate for oral inflammation
|
|
AU2013211531A1
|
|
Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
|
|
EP2525660A1
|
|
Modified release formulation and methods of use
|
|
SG182644A1
|
|
Modified release formulation and methods of use
|
|
KR20110052641A
|
|
Modified release formulation and methods of use
|
|
EP2310369A1
|
|
Benzyloxy anilide derivatives useful as potassium channel modulators
|
|
AU2008308849A1
|
|
Silicone gel-based compositions for wound healing and scar reduction
|
|
US2009137635A1
|
|
Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
|
|
WO2008157802A1
|
|
3-hydroxyisothiazole-4-carboxamidine derivatives as chk2 inhibitors
|
|
US2008318979A1
|
|
Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
|
|
WO2008066900A1
|
|
1,4 diamino bicyclic retigabine analogues as potassium channel modulators
|
|
SG174095A1
|
|
Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
|
|
US2008146661A1
|
|
Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
|
|
WO2006133417A1
|
|
Phenylamino isothiazole carboxamidines as mek inhibitors
|
|
US7056895B2
|
|
Tirazole nucleoside analogs and methods for using same
|
|
US6743902B1
|
|
Sugar modified nucleosides
|
